{"ModuleTitle": "Company Description", "CompanyName": "Vertex Pharmaceuticals Incorporated", "Symbol": "VRTX", "Address": "50 NORTHERN AVENUE, BOSTON, Massachusetts, 02210, United States of America", "Phone": "6173416393", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We invest in scientific innovation to create transformative medicines for people\r\nwith serious diseases with a focus on specialty markets.\r\nCystic Fibrosis\r\nOur goal is to develop treatment regimens that will provide benefits to all\r\npatients with cystic fibrosis, or CF, and will enhance the benefits that\r\ncurrently are being provided to patients taking our medicines. Our marketed\r\nmedicines are TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and\r\nivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI\r\n(lumacaftor/ivacaftor) and KALYDECO (ivacaftor). We obtained approval from the\r\nU.S. Food and Drug Administration, or the FDA, for TRIKAFTA, our triple\r\ncombination regimen, in October 2019.  This approval increased the number of\r\npatients eligible for our medicines in the U.S. by approximately 6,000 and\r\nprovided an additional treatment option for many patients who are also eligible\r\nfor one of our previously approved products.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f13%2f0000875320-20-000007.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Carmen Bozic", "title": "Chief Medical Officer"}, {"name": "Charles F. Wagner", "title": "Chief Financial Officer & Executive Vice President"}, {"name": "David Matthew Altshuler", "title": "Chief Scientific Officer & EVP-Global Research"}, {"name": "Mike Tirozzi", "title": "Senior VP, Chief Information & Data Officer"}, {"name": "Reshma Kewalramani", "title": "President, Chief Executive Officer & Director"}], "Number_of_employees": ["3,000"], "Subsidiaries": ["NO INFO"]}